X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
NV-CoV-2 (NV-387) was designed to mimic sulfated proteoglycans that a large number of virus families bind to as the first step in infecting a cell. It may possess significant antiviral activity against many other virus families in addition to COVID-19, MPox and Smallpox virus infections.
Lead Product(s): NV-387
Therapeutic Area: Infections and Infectious Diseases Product Name: NV-CoV-2
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 30, 2024
Details:
The drug NV-CoV-2 contains the Company's nanoviricide active agent, NV-387, which has shown strong broad-spectrum antiviral activity not only against multiple coronaviruses, but also against RSV and in a model for Smallpox therapeutics.
Lead Product(s): NV-387
Therapeutic Area: Infections and Infectious Diseases Product Name: NV-CoV-2
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 28, 2023
Details:
NV-CoV-2 (NV-387) was designed to mimic sulfated proteoglycans that a large number of virus families bind to as the first step in infecting a cell. It may possess significant antiviral activity against many other virus families in addition to MPox and Smallpox virus infections.
Lead Product(s): NV-387
Therapeutic Area: Infections and Infectious Diseases Product Name: NV-CoV-2
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 14, 2023
Details:
NV-CoV-2 (NV-387) was designed to mimic sulfated proteoglycans that a large number of virus families bind to as the first step in infecting a cell. It may possess significant antiviral activity against many other virus families in addition to coronaviruses.
Lead Product(s): NV-387
Therapeutic Area: Infections and Infectious Diseases Product Name: NV-CoV-2
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 21, 2023
Details:
NV-CoV-2 (NV-387) is a first-in-class chemical nanomachine that acts by a novel mechanism of action is re-Infection blocker. which is invetigated for the treatment of covid-19 infection.
Lead Product(s): NV-387
Therapeutic Area: Infections and Infectious Diseases Product Name: NV-CoV-2
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 11, 2023
Details:
NV-CoV-2 (NV-387) is a first-in-class chemical nanomachine that acts by a novel mechanism of action is re-Infection blocker. which is invetigated for the treatment of covid-19 infection.
Lead Product(s): NV-387
Therapeutic Area: Infections and Infectious Diseases Product Name: NV-CoV-2
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 29, 2023
Details:
NV-CoV-2 (NV-387) was designed to mimic sulfated proteoglycans that a large number of virus families bind to as the first step in infecting a cell. It may possess significant antiviral activity against many other virus families in addition to coronaviruses.
Lead Product(s): NV-387
Therapeutic Area: Infections and Infectious Diseases Product Name: NV-CoV-2
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 25, 2023
Details:
Under this Agreement, Karveer has the right to commercialize the Company's COVID drugs NV-CoV-2 and NV-CoV-2-R in India. To enable commercialization, Karveer has undertaken Clinical Development and Evaluation and is sponsoring these two drugs in India for this purpose.
Lead Product(s): NV-CoV-2
Therapeutic Area: Infections and Infectious Diseases Product Name: NV-CoV-2
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Karveer Meditech
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement April 04, 2023
Details:
The Company has also demonstrated the ability of NV-387 to encapsulate and improve the pharmacokinetics and pharmacodynamics of a very difficult drug, namely remdesivir, that is formulated in a cyclodextrin-based formulation at present (Veklury® Gilead).
Lead Product(s): Tecovirimat,NV-387
Therapeutic Area: Infections and Infectious Diseases Product Name: NV-387
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 04, 2022
Details:
In this well-known assay, NV-CoV-2 was as effective as the neutralizing antibody in reducing the virus infection. This study demonstrates that NV-CoV-2 attacks the SARS-CoV-2 pseudovirion particles and renders them incapable of binding to the ACE2 positive cells.
Lead Product(s): NV-Cov-2,Remdesivir
Therapeutic Area: Infections and Infectious Diseases Product Name: NV-Cov-2-R
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 11, 2021
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
